11.12.09
Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference

9.18.09
Tobira ICAAC 2009 Poster -TBR-652, A CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST, DEMONSTRATES GOOD ORAL BIOAVAILABILITY AND DESIRABLE PHARMACOKINETIC (PK) AND SAFETY PROFILES IN HEALTHY VOLUNTEERS

9.18.09
Tobira ICAAC 2009 Poster - IN VITRO ANTI-HIV EFFICACY OF THE CHEMOKINE RECEPTOR 5 (CCR5) ANTAGONIST TBR-652 IN COMBINATION WITH FOUR OTHER CLASSES OF ANTIRETROVIRAL AGENTS

7.22.09
Tobira IAS 2009 Poster - Effect of Food on the Relative Bioavailabiliy and Pharmacokinetics of TBR652

7.22.09
Tobira IAS 2009 Poster 2 - Pharmacokinetics, Safety and Tolerabilityof Single Doses of TBR652 in Healthy Volunteers

7.22.09
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

6.4.09
Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board

4.8.09
Tobira Therapeutics Inc. Initiates Proof of Concept Study with TAK-652 for the Treatment of HIV

9.18.08
In September 2008, Tobira Therapeutics and Kureha Corporation entered into an exclusive evaluation agreement to evaluate KRH-3166, a CXCR4 antagonist in the treatment of HIV-1 infection.  CXCR4 is a human chemokine receptor shown to be required for infection by human immunodeficiency virus (HIV).   KRH-3166 is a pro-drug to KRH-3153 and KRH-3140. Tobira has exclusive rights to evaluate and select a lead compound over the course of two years.  The CXCR4 antagonist provides an additional mechanism of action to combat HIV.

8.18.08
Tobira Therapeutics Inc. Receives US Patent for TBR-652

6.30.08
Tobira Therapeutics Inc. Announces Senior Management Team Senior management team possessing over 130 years of cumulative expertise